S.2 Ep. 6 | Beyond the Headlines

Streaming now on: Amazon Music  |  Apple Podcasts  |  Spotify  |  Soundcloud  |  YouTube

Learn More About Beyond the Endpoint  |  View All Episodes

In this special "Beyond the Headlines" episode recorded at the 2025 American Heart Association Scientific Sessions in New Orleans, hosts Manesh Patel and Emily O’Brien share highlights from one of cardiovascular medicine's most anticipated annual gatherings. The duo discusses late-breaking science, including a potential gene-editing therapy for cholesterol management, PCSK9 inhibitors in primary prevention of major cardiac events, and new findings on atrial fibrillation management. They explore the implications of left atrial appendage occlusion devices compared to anticoagulation, the potential to discontinue blood thinners after successful ablation, and, perhaps most important for coffee lovers, the DECAF trial's findings on caffeine and heart rhythm. From cutting-edge genomics to practical patient care decisions, this episode captures the energy and innovation driving cardiovascular medicine forward.

Related Headlines from this Episode

• First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides
• PCSK9 inhibitor reduced major CVD events in adults with no prior heart attack or stroke
• Cup of coffee a day may not be harmful for some adults with AFib and could lower episode
• DCRI reveals new results, shares expert insights at AHA25